AOC1 (Gene)

Organism:

Homo sapiens

Synonyms:ABP, ABP1, AOC1, DAO, DAO1, ENTREZ:26, HGNC:80, KAO, MIM:104610, NM_001091, NM_001272072, NP_001082, NP_001259001, XM_017011944, XM_017011945, XM_017011946, XM_017011947, XP_016867433, XP_016867434, XP_016867435, XP_016867436, amine oxidase copper containing 1

Omim:OMIM:104610

Id:28b4ce8d-6b01-51ca-8d20-14d50b8fc1f6

Hgnc:HGNC:80

Entrez:26

Ensembl:ENSG00000002726

Description:amine oxidase copper containing 1

This gene encodes a metal-binding membrane glycoprotein that oxidatively deaminates putrescine, histamine, and related compounds. The encoded protein is inhibited by amiloride, a diuretic that acts by closing epithelial sodium ion channels. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Jan 2013]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View AOC1's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with AOC1.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using AOC1.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for AOC1.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with AOC1.

Results found

Linked to

	Label	Description
	GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE158632 3 V 5 OXYQUINOLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 6 V 5 CRIZOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 11 v 12 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE232944 APC CTNNB1 overexpression HT29 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 1 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE185519 3 V 5 GILTERITINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE158632 3 V 5 OXYQUINOLINE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 6 V 5 CRIZOTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 3 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE108464 AZ-628 11 v 12 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE232944 APC CTNNB1 overexpression HT29 1 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 1 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE185519 3 V 5 GILTERITINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.